Physician profile
Daniel Lee
NPI 1417417627
$1,629.33
in general payments reported to CMS, 2019-2025
10 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872 · Travel and Lodging: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.51 |
| Travel and Lodging | $757.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $920.74 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertex Pharmaceuticals Incorporated | $253.79 | 2025 | |
| Abbvie INC. | $188.88 | 2025 | |
| Ibsa Pharma INC. | $79.13 | 2025 | Licart, Flector, Tirosint |
| Merz Pharmaceuticals, LLC | $55.78 | 2025 | Xeomin |
| Zimmer Biomet Holdings, INC. | $45.80 | 2025 | G7 |
| Tersera Therapeutics LLC | $32.39 | 2025 | Prialt |
| Pfizer INC. | $19.38 | 2025 | |
| Solventum Corporation | $18.37 | 2025 | V.A.C. Veraflo Cleanse Choice, Prevena, V.A.C. Veraflo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.07 | 2025 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.